TCM
FLGT icon

Triumph Capital Management’s Fulgent Genetics FLGT Stock Holding History

Triumph Capital Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$88 Hold
4
– – ﹤0.01% 1876
2026
Q2 		$82 Hold
4
– – ﹤0.01% 1831
2026
Q1 		$64 Hold
4
– – ﹤0.01% 1811
2025
Q4 		$105 Buy
+4
New +$104 ﹤0.01% 1739

Other funds holding FLGT

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
ATC
Adirondack Trust Company Saratoga Springs, New York $320M AUM 23.25% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Triumph Capital Management's FLGT Position: Q3 2026 in Review

Triumph Capital Management held its Fulgent Genetics (FLGT) position steady in Q3 2026 at 4 shares worth $88. The position accounts for ﹤0.01% of the portfolio, ranked #1876.

Triumph Capital Management first reported a position in FLGT in Q4 2025 and has held it in 4 quarters since. The position peaked at $105 in Q4 2025. 10 funds tracked by Wall St. Rank hold FLGT as of Q3 2026.

  • Triumph Capital Management held 4 shares of Fulgent Genetics worth $88 as of Q3 2026.
  • Triumph Capital Management left its Fulgent Genetics share count unchanged in Q3 2026.
  • Fulgent Genetics made up ﹤0.01% of Triumph Capital Management's portfolio in Q3 2026, its #1876 holding.
  • Triumph Capital Management first reported a position in Fulgent Genetics in Q4 2025 and has held it in 4 quarters since.
  • Triumph Capital Management's Fulgent Genetics position peaked at $105 in Q4 2025.
  • 10 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2026.

Based on Triumph Capital Management's 13F filing for Q3 2026, filed 14 Oct 2026.